The FDA has denied Eli Lilly's appeal of the agency's ruling requiring it to conduct an additional three-year study of ruboxistaurin mesylate (Arxxant) before it can be approved for treating diabetic retinopathy (DR).
APAO 2023: Keralink Trial and efficacy safety of corneal cross-linking for children with Keratoconus
February 25th 2023The Keralink Trial was the first randomized clinical trial that tested the hypothesis that corneal cross-linking (CXL) might decrease keratoconus progression in children compared with the use of spectacles or contact lenses.
2 Clarke Drive
Cranbury, NJ 08512